



Lohmann & Rauscher

## Debrisoft® Pad and Lolly


Break down the barriers to wound healing.

Gentle debridement for effective wound bed preparation.



# See the Debrisoft® Difference through clinical outcomes.

Before debridement




After debridement with Debrisoft®




## Mixed leg ulcer<sup>5</sup>

Debrisoft was first used to remove the dense fibrinous membrane from the outer wound bed. Next sharp debridement was used to remove the eschar in the center of the wound bed. Finally, Debrisoft was again utilised to remove the remaining necrotic remnants<sup>4</sup>.



## Leg ulcer

Leg ulcer covered in thick yellow slough. Result after 2-4 minutes of debridement with Debrisoft. A single use made an instant difference to both the wound and patient<sup>9</sup>.



## Amputation

Trans-metatarsal amputation showing exudate and necrotic tissue after removal of dressing and after 3-4 minute debridement with Debrisoft<sup>4</sup>.




## Open abdomen

Debridement with Debrisoft Lolly was atraumatic and showed significant reduction of bacterial bioburden through removal of devitalised tissue and infected loose mesh<sup>10</sup>.


# There is only one Debrisoft®

## Discover its unique benefits.




### Clinically-proven<sup>1,2</sup>

- Reduces 90%–99% of slough, biofilm, and bacterial load<sup>3</sup>



### Visible results in 2–4 minutes<sup>1</sup>

- Saving time and money



### Virtually painless<sup>2</sup>


- 97.4% report no pain or side effects




### Safe debridement<sup>1,2</sup>

- Granulation tissue is protected
- Easy to use


## Mode of action



The fibre composite material of Debrisoft consists of 100% **knitted monofilament polyester fibers**.



Beveled fibre tips loosens debris effectively while **protecting newly formed granulation tissue** and epithelial cells.



Fibre composite **lifts, binds, and removes** slough and debris, including biofilm.

# Debridement

## The first step in wound treatment and effective wound bed preparation.

Necrosis, slough, biofilm and debris trap the wound in the inflammatory phase of wound healing. Effective debridement helps to remove these inflammatory stimulants and to reduce the associated physical and biochemical mediators, matrix metallo-proteinases (MMPs) and cytokines that degrade the wound and prevent it from progressing to the proliferative phase of wound healing.

Devitalised tissue and hyperkeratosis can interfere with the accurate assessment of the wound and surrounding skin, delaying appropriate follow-on treatment or reducing the effectiveness of topical preparations. Debridement helps expose the wound bed for accurate wound assessment and allows topical medications to reach the skin to deliver therapeutic benefits. Numerous studies have shown that debridement enhances wound healing.<sup>6,2,8</sup>

The main debridement challenges are:

- Pain for the patient
- Trauma to healthy and newly formed tissue
- Cost, time, number of procedures
- Training of healthcare provider

**Debrisoft® solves these debridement challenges.**

### What is Debrisoft®?

Debrisoft® is a unique, clinically proven, safe, and time saving mechanical debridement product that cleans chronic, traumatic, and superficial wounds, peri-wound, and hyperkeratotic skin. Additionally, with Debrisoft Lolly, deep, undermining or tunneling wounds can be debrided when other debridement methods cannot be used.

### Effectiveness Evaluation

The National Institute for Health and Care Excellence (NICE) develops guidance, standards, and information on high-quality health and social care, and determines what drugs and treatments are available in the UK. NICE evaluated Debrisoft® and released the Debrisoft NICE Guidance at the end of March 2014 with a subsequent update in March 2019 to also include Debrisoft pad 13x20cm and Debrisoft Lolly. The NICE guidance supports the case that L&R's Debrisoft provides both multiple patient health benefits as well as significant cost savings for the National Health Service (NHS).

### Conclusion

The conclusion of the NICE guidance committee was that by using Debrisoft on appropriate wounds, these wounds would be “fully debrided more quickly, with fewer nurse visits needed compared with other debridement methods. In addition, the Debrisoft is convenient and easy to use, and is well tolerated by patients.”

They found that Debrisoft:

- Is more effective at debridement than the common practice of using autolytic dressings and irrigating wounds with saline or cleansing with gauze.
- Results in less frequent and fewer overall care visits
- Reduces risk of trauma to healthy tissue and reduces bleeding
- Contributes to overall cost savings compared with current practices

# Debrisoft® Pad and Lolly

## Indications


Debrisoft is intended for rapid and effective debridement of wounds.

Debrisoft Lolly is intended for the debridement of deep to superficial wounds for wound bed preparation.

Including:

- diabetic ulcers
- arterial and venous ulcers
- postoperative wounds healing by secondary intention
- trauma, burns/scalds

Debrisoft Lolly is used to absorb exudate, debris and keratosis during debridement.



## Application



### Step 1

Open the Debrisoft single-use sterile pack.



### Step 2

Moisten the soft, fleecy part of the product with tap water or saline solution, as per protocol. Recommended amount:  
Debrisoft pad 10x10cm: 20-40ml  
Debrisoft pad 13x20cm: 90-110ml  
Debrisoft Lolly: 5-15ml  
Always refer to local guidelines.  
Do not wring or cut.



### Step 3

Gently with controlled pressure, use the soft, fleecy part of the product in a circular motion or long sweeping strokes. Use a new Debrisoft for each separate wound/area of skin.



### Step 4

Dispose of the used product in normal clinical waste.

Refer to the IFU for full instructions and precautions.

Always moisten  
Debrisoft before use.



## Sources:

1. Haemmerle, G., Duelli, H., Abel, M., Strohal, R. (2011), "The wound debrider: a new monofilament fibre technology", British Journal of Nursing, TV Supplement Vol. 20(6) March
2. Bahr, S., Musta, N., Hattig, P., Piatkowski, A., Mosti, G., Reimann, K., Abel, M., Dini, V., Restelli, J., Babadagi-Hardt, Z., Abbritti, F., Eberlein, T., Wild, T., Bandl, K., Schmitz, M. (2010), "Clinical efficacy of a new monofilament fibre-containing wound debridement product", Journal of Wound Care, Vol 20 (5) May
3. Schultz, G. (2015), "Effect of Debrisoft debridement of pseudomonas aeruginosa mature biofilm on pig skin explants", 2015 EWMA Conference, London, GB
4. Cuttino, C., Weir, D. (2016), "Use of a Novel Device for Selective Mechanical Debridement of Chronic Wounds", 2016 SAWC Spring, Atlanta, USA
5. Alridge, P., Brindle, T., D'Mello-Fernandes, V. (2015), "Gentle, Cost-Effective Debridement for All: The Microfiber Debridement Pad", 2015 SAWC Fall, Las Vegas, USA
6. Attinger, C.E., et al. (2006), "Clinical approach to wounds: debridement and wound bed preparation including the use of dressings and wound-healing adjuvants.", Plastic and reconstructive surgery, 117(7): 72-109
7. National Institute for Health and Care Excellence (2014), "The Debrisoft® monofilament debridement pad for use in acute or chronic wounds", NICE medical technology guidance MTG17, accessed: <https://www.nice.org.uk/Guidance/MTG17>
8. Strohal, R., Apelqvist, J., Dissemond, J. et al (2013), "EWMA Document: Debridement.", J Wound Care; 22(Suppl.1):p1-p52.
9. Ousey, K., Fumarola, S., Cook, L. and Bianchi, J. (2012), "The Missing Link: the key to improved wound assessment". Case Study. British Journal of Nursing, London.
10. Orig, R. (2017), "Debridement over bowel using a Monofilament Fibre Lolly", 2017 EWMA Conference

## Ordering Information

### Debrisoft®

sterile, individually-sealed

Size	REF	Shipping Units (per box/case)
10 cm x 10 cm	34322	5/50
<b>NEW</b> 13 cm x 20 cm	136323	5/50

### Debrisoft® Lolly

sterile, individually-sealed

REF	Shipping Units (per box/case)
33224	5/50



## Experience Debrisoft® for yourself.

Contact Lohmann & Rauscher for your Debrisoft® sample pack.

AUS: 1300 572 869

NZ: 0800 572 869

Email: [info@au.LRmed.com](mailto:info@au.LRmed.com)

Debrisoft® is a registered trademark of Lohmann & Rauscher GmbH & Co KG. © 2018

Lohmann & Rauscher Pty Ltd · 321 Ferntree Gully Road · Mount Waverley, Victoria 3149, Australia · Customer Service: 1300 572 869

Lohmann & Rauscher Limited · 21 Queen Street · Auckland 1010 · New Zealand · Customer Service: 0800 572 869

[www.Lohmann-Rauscher.com.au](http://www.Lohmann-Rauscher.com.au)